Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain

Abstract

(2) and London mutation(s) (3) alter APP processing, causing increased production of the A␤ peptide of 42 amino acids (4), hypothesized to be pivotal in AD pathology (1, 5). Early onset familial AD caused by mutations in the presenilin genes supports this hypothesis, because they increase production of A␤ (42) peptide (6, 7) due to the gain of an unknown function (8). The extensive cell biological definition of the metabolic effects of the different mutations in APP in vitro requires matching analysis of their physiological impact in vivo. Transgenic mice with wild type and different mutant forms of APP have been generated and the original, most wanted end point, i.e. AD-like amyloid plaques in mouse brain, was obtained (9, 10), accompanied by cognitive deficits (11) and by hyperphosphorylation of protein tau (12). In other transgenic mouse strains overexpression of APP caused behavioral, synaptotrophic, and neurodegenerative effects, accelerated senescence, and premature death, in the absence of amyloid deposits (13-16). Intracellular expression of the A␤ peptide yielded mice with extensive neuronal loss but no amyloidosis (17). Overexpression of the C-terminal domain of APP caused neuronal degeneration (18), whereas in another model, pre-amyloid deposits, hippocampal cell loss, and cognitive deficits were documented (19).We have generated additional transgenic mouse strains, expressing human APP, either wild type or the London or Swedish clinical mutations, from the neuron-specific mouse thy-1 gene promoter. Their phenotype was analyzed by biochemical, histochemical, behavioral, electrophysiological, and pharmacological methods. Measurements of different APP metabolites in brain demonstrated that increased A␤(42) levels correlated with the formation of amyloid plaques in the brain of old APP/London transgenic mice. The plaques were extensively characterized immunohistochemically and displayed many aspects typically observed in the brain of AD patients. As opposed to plaques that developed only after at least 12 months of age, other deficits were observed from 3 months onwards and included cognitive impairment, decreased long term potentiation, differential glutamatergic responses, aggression, and neophobia, among others. These signs were largely independent of the actual isoform or mutant of APP that was expressed, were not correlated with a single APP metabolite, and are dissociated in time from plaque formation. These mice will be good models to study both early and late, neuropathological, and clinical aspects related to Alzheimer's disease. EXPERIMENTAL PROCEDURESGeneration of Transgenic Mice-cDNA coding for human wild type APP (695 isoform), the Swedish (K670N,M671L) mutant (770 isoform), and the London (V642I) mutant (695 isoform) were cloned in the pTSC vector in the mouse thy-1 gene (16). The purified, linearized minigenes were microinjected into prenuclear embryos from superovulated FVB/N females.Antibodies-Rabbit antisera B11/4 and B12/4, generated against a *

Overexpression of Hsp27 ameliorates symptoms of Alzheimer's disease in APP/PS1 mice

“…Our results have shown that LTP was impaired in APPswe/PS1dE9 mice indeed, but it was normalized upon Hsp27 overexpression. There is substantial evidence from transgenic mouse models that intracellular Aβ initiates cellular dysfunction, synaptic, electrophysiological, and behavioral changes before it accumulates in extracellular plaques (Moechars et al 1999;Kumar-Singh et al 2000;Mucke et al 2000). The toxic Aβ molecules (either soluble oligomers or fibrillar forms) might initiate a cascade, which finally leads to neuronal dysfunction.…”

Spatial relationship between synapse loss and β‐amyloid deposition in Tg2576 mice

“…Morphological studies also indicate that Aβ oligomers can accumulate within neuronal processes (Takahashi et al, 2004;Kokubo et al, 2005). Several studies have demonstrated that soluble Aβ can disrupt synaptic function and impair LTP (Larson et al, 1999;Moechars et al, 1999;Chapman et al, 1999;Cleary et al, 2005). In support of the hypothesis that soluble Aβ can be neurotoxic, we also found decreases in synapse density in the outer molecular layer of the dentate gyrus in Tg2576 mice at an age when soluble Aβ is typically increased (i.e., 6-9 months of age), but when plaque deposition is minimal (Holcomb et al, 1998).…”

Ketone Bodies as a Therapeutic for Alzheimer's Disease

“…These animals exhibit significant levels of soluble A␤ in as few as 3 months of age, and extensive plaque deposition by 12 to 14 months. 45 Six- 44 ; open access article.) teen, 3-month-old, female mice were fed either a ketogenic chow or standard chow for 43 days.…”